JG
MCRB icon

Jefferies Group’s Seres Therapeutics MCRB Stock Holding History

Jefferies Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,000
Closed -$481K – 2804
2019
Q3 		$481K Hold
6,000
– – ﹤0.01% 1910
2019
Q2 		$386K Buy
+6,000
New +$569K ﹤0.01% 1801

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's MCRB Position: Q3 2019 in Review

Jefferies Group sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 230 shares — an estimated $15.2K sold.

Jefferies Group first reported a position in MCRB in Q2 2018 and held it in 5 quarters. The position peaked at $169K in Q1 2019. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

  • Jefferies Group reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Jefferies Group sold 230 Seres Therapeutics shares in Q3 2019, an estimated $15.2K.
  • Jefferies Group first reported a position in Seres Therapeutics in Q2 2018 and held it in 5 quarters.
  • Jefferies Group's Seres Therapeutics position peaked at $169K in Q1 2019.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.